Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)
This study has been terminated.
(The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a futility analysis with 55 randomized children.)
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
First received: May 8, 2007
Last updated: April 30, 2012
Last verified: April 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||March 2007|
|Estimated Primary Completion Date:||No date given|
Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Zeiger RS, Chinchilli VM, Martinez FD, Lemanske RF Jr, Taussig LM, Mauger DT, Morgan WJ, Sorkness CA, Paul IM, Guilbert T, Krawiec M, Covar R, Larsen G; CARE Network. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol. 2008 Dec;122(6):1138-1144.e4. doi: 10.1016/j.jaci.2008.09.028. Epub 2008 Oct 25.